Wen Kong

Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis

Wen Kong, Yunze Xu, Guiqin Liu, Wenwen Lv et autres

cn (code pays fourni par la source)

Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysis

Jin Zhang, Wen Kong, Yi Xu, Guiqin Liu et autres

cn (code pays fourni par la source)

A multimodal AI model for precision prognosis in clear cell renal cell carcinoma: A multicenter study

Yujia Xia, Haibing Xiao, Haolun Luo, Minggui Si et autres

cn, tw, hk (code pays fourni par la source)

Efficacy prediction and prognostic analysis on immunotherapy and TKIs combination treated mRCC by customized tumor-informed ctDNA-MRD.

Zhengwei Wu, Di Wu, Qiong Chen, Wen Kong et autres

cn (code pays fourni par la source)

IP12-29 A PHASE II STUDY OF TISLELIZUMAB AS NEOADJUVANT TREATMENT FOR CISPLATIN-INELIGIBLE HIGH RISK UPPER TRACT UROTHELIAL CARCINOMA

Jiwei Huang, Xingyun Cai, Cheoklong Ng, Qiong Chen et autres

IP12-28 TUMOR-INFORMED MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN BLOOD AND URINE PREDICTS RECURRENCE AND METASTASIS IN PATIENTS WITH SURGICALLY CURED UPPER TRACT UROTHELIAL CARCINOMA (UTUC): A PROSPECTIVE COHORT STUDY

Jiwei Huang, Qiong Chen, Xun Wang, Cheoklong Ng et autres

A0586 – Tumor-informed minimal residual disease (MRD) detection in blood and urine predicts recurrence and metastasis in patients with surgically cured upper tract urothelial carcinoma (UTUC): A prospective cohort study

Junfeng Huang, Qin Chen, Xuming Wang, Calvin S.H. Ng et autres

A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma

Jiwei Huang, Xingyun Cai, Cheoklong Ng, Yuansheng Luo et autres

cn (code pays fourni par la source)

Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.

Wen Kong, Guangyu Wu, Yunze Xu, Zaoyu Wang et autres

cn (code pays fourni par la source)

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.

Jianhui Qiu, Jingcheng Zhou, Lin Cai, Wen Kong et autres

cn, us (code pays fourni par la source)

Tislelizumab Plus Lenvatinib as the First-Line Therapy in Patients with Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Arm, Single-Centre, Phase 2 Trial and Metabolic Biomarker Analysis

Wen Kong, Yunze Xu, Guiqin Liu, Zaoyu Wang et autres

cn (code pays fourni par la source)

Contemporary Incidence of Cognitive Impairment or Dementia in Patients Undergoing Coronary Artery Bypass Grafting: A Systematic Review and Meta-Analysis

Hong K. Lo, Christopher Eing Wee, Candice Low, Yao Hao Teo et autres

au, sg (code pays fourni par la source)